Doxorubicin delivery by pYEEIE peptide-functionalized rhodiola rosea-derived exosome-like nanovesicles for targeted melanoma therapy
Frontiers in Pharmacology · 28.07.2025 · 16
DOI: 10.3389/fphar.2025.1619998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.07.2025. Verfasst von Meitao Duan und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Research Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Melanoma is the most common cause of skin cancer-related deaths due to its aggressive nature. Plant-derived exosome-like nanovesicles (PELNs) are promising natural nanoparticles for therapeutic applications owing to their biocompatibility and diverse bioactive components. However, research on Rhodiola rosea-derived exosome-like nanovesicles (RELNs) remains limited.
Methods
This study evaluated the therapeutic efficacy and safety of a novel targeted drug delivery system, pYEEIE peptide-functionalized RELNs loaded with doxorubicin (DOX) (pYEEIE-RELNs-DOX), in melanoma-bearing mice.
Results
Fluorescence imaging and histopathological assessments demonstrated that pYEEIE-RELNs-DOX exhibited superior tumor-targeting ability and significantly inhibited melanoma growth compared to free DOX and non-targeted RELNs-DOX. Importantly, pYEEIE-RELNs-DOX showed no toxicity to major organs (heart, liver, spleen, lungs, and kidneys), whereas free DOX induced cardiac tissue damage. Meanwhile, the serum ALT and AST levels remained normal, indicating no liver cell damage.
Conclusion
These findings highlight the potential of pYEEIE-RELNs-DOX as a low-toxicity, high-efficacy targeted delivery system for melanoma therapy, providing a foundation for clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Research Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, China.
- Xiamen Xianyue Hospital, Xiamen Xianyue Hospital Affiliated with Xiamen Medical College, Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen, Fujian, China.
- Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Xiamen, China.
- Guangzhou HC Pharmaceutical Co., Ltd., Guangzhou, China.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Zitieren
APA
Duan, M., Chen, B., Yi, X., Mahal, A., Song, L., Xu, M., Obaidullah, A. J., Yu, S., & Wang, C. (2025). Doxorubicin delivery by pYEEIE peptide-functionalized rhodiola rosea-derived exosome-like nanovesicles for targeted melanoma therapy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1619998
Vancouver
Duan M, Chen B, Yi X, Mahal A, Song L, Xu M, et al. Doxorubicin delivery by pYEEIE peptide-functionalized rhodiola rosea-derived exosome-like nanovesicles for targeted melanoma therapy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1619998
BibTeX
@article{Duan2025,
author = {Duan, Meitao and Chen, Binbin and Yi, Xue and Mahal, Ahmed and Song, Linwei and Xu, Moxun and Obaidullah, Ahmad J and Yu, Shuwei and Wang, Chen},
title = {Doxorubicin delivery by pYEEIE peptide-functionalized rhodiola rosea-derived exosome-like nanovesicles for targeted melanoma therapy},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1619998}
}
EUVIMED